Evidence map›Paper›PMID 39696329›Full record

ArticleBMC health services research2024

Burden of invasive pneumococcal disease, non-invasive all-cause pneumonia, and acute otitis media in hospitalized US children: a retrospective multi-center study from 2015 to 2020.

Salini Mohanty, Nicole Cossrow, Meghan White, Kalvin C Yu, Gang Ye, Kristen A Feemster, Vikas Gupta

Abstract readMulticenter Study
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Salini MohantyOutcomes Research, Merck & Co., Inc, 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ, 07065, USA. salini.mohanty@merck.com.
Nicole CossrowOutcomes Research, Merck & Co., Inc, 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ, 07065, USA.
Meghan WhiteOutcomes Research, Merck & Co., Inc, 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ, 07065, USA.
Kalvin C YuBecton, Dickinson & Company, Franklin Lakes, NJ, USA.
Gang YeBecton, Dickinson & Company, Franklin Lakes, NJ, USA.
Kristen A FeemsterGlobal and Medical Scientific Affairs, Merck & Co., Inc, Rahway, NJ, USA.
Vikas GuptaBecton, Dickinson & Company, Franklin Lakes, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite effective pneumococcal vaccines, pneumococcal disease (PD) exerts a substantial burden on children. This study explored the clinical and economic burden of invasive PD (IPD), non-invasive all-cause pneumonia (ACP), and acute otitis media (AOM) in hospitalized children.

methodsData from the BD Insights Research Database of hospitalized children (< 18 years, including infants and children) in the US were analyzed retrospectively. The study cohort included patients with an ICD10 code for IPD, ACP, or AOM and/or a positive culture for S. pneumoniae. Descriptive statistics and multivariable analyses evaluated the following outcomes: length of stay [LOS], hospital cost per admission, hospital margin per admission [costs - payments], and in-hospital mortality.

resultsThe study included 4575 pediatric patients with IPD (n = 36), ACP (n = 3,329), or AOM (n = 1,210) admitted to 57 US hospitals from October 2015 to February 2020. Approximately half (50.7%) were under 2 years of age. The in-hospital mortality rate was 0.6% (n = 28). The observed median (interquartile range) LOS was 4 (3, 5) days, cost per admission was $4,240 ($2,434, $8,311) US dollars, and hospital margin per admission was -$63 ($2,118, $2,025). LOS and costs were highly variable according to clinical characteristics and hospital variables. Key variables associated with poor outcomes were having a moderate- or high-risk condition (chronic or immunocompromising), intensive care unit admission, and prior 90-day admission.

conclusionsThe burden of PD among hospitalized pediatric patients in the US remains substantial. Our study highlights the burden of PD among young children (< 2 years) and children with underlying medical conditions that put them at greater risk for PD. The results support the need for ongoing prevention efforts including vaccination and antimicrobial stewardship programs to reduce the burden of PD in children.

Indexed as

Otitis MediaPneumococcal InfectionsAcute DiseaseAdolescentChildChild, PreschoolCost of IllnessFemaleHospital CostsHospitalizationHospital MortalityHumansInfantLength of StayMalePneumoniaAntimicrobial resistanceChildrenCostsHospitalizationPneumococcal diseaseStreptococcus pneumoniae

Identifiers

PMID39696329
PMCPMC11653741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.